Breaking News

Financial Reports: Gilead

By Gil Roth | February 5, 2014

Stribild, Complera/Eviplera drive growth

Gilead 4Q13

4Q Revenues: $3.1 billion (+21%)

4Q Earnings: $791 million (+4%)

FY Revenues: $11.2 billion (+15%)

FY Earnings: $3.1 billion (+19%)

Comments: Product sales rose 21% in 4Q to $3.0 billion, driven by Stribild (+409% to $204 million), and Complera/Eviplera (+122% to $262 million). Atripla sales rose 2% to $934 million. In FY13, Atripla sales were up 2% to $3.6 billion, while Stribild posted $539 million (+837%) and Complera/Eviplera had $809 million in revenues (+137%). Gilead's cardiovascular franchise posted 24% gains in FY, with Letairis posting $520 million in sales (+27%) and Ranexa adding $449 million (+20%).
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks